Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04026256 · ClinicalTrials.gov registry record · Phase 4
Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 37
- Enrollment target
NCT04026256: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT04026256 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 37 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04026256, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 37 participants
- Enrollment target
Study Summary
The purpose of this study is to examine, via iliac crest bone biopsies, the mechanism of combined teriparatide and denosumab on the bone of postmenopausal osteoporotic women after 3 months of treatment.
Interventions
- DRUG Denosumab
- DRUG Teriparatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2019-09-02 |
| Est. Completion | 2022-04-18 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04026256
The ClinicalTrials.gov registry entry for NCT04026256 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Denosumab is the first listed.
NCT04026256 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04026256 about?
NCT04026256 is a clinical study titled "Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration". The purpose of this study is to examine, via iliac crest bone biopsies, the mechanism of combined teriparatide and denosumab on the bone of postmenopausal osteoporotic women after 3 months of treatment.
What is the current status of trial NCT04026256?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 37 participants. The study started on 2019-09-02. Estimated completion is 2022-04-18.
What interventions are being tested in trial NCT04026256?
The interventions under investigation include: Denosumab (DRUG), Teriparatide (DRUG).
Who is sponsoring clinical trial NCT04026256?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.